Ipatasertib combined with non-taxane chemotherapy for patients with previously treated advanced triple-negative breast cancer: the PATHFINDER phase IIa trial

Abstract Background The PI3K/AKT pathway is frequently altered in advanced triple-negative breast cancer (aTNBC), representing a promising target. Ipatasertib, a pan-AKT inhibitor, has shown activity with taxane-based chemotherapy and acceptable safety. This study evaluated the safety and efficacy o...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Elena López-Miranda, Jose Manuel Pérez-García, María Gión, Nuria Ribelles, Patricia Cortez-Castedo, José Luis Alonso-Romero, María Martínez García, Santiago González-Santiago, Begoña Bermejo, Serafín Morales, Vicente Carañana, Laia Garrigós, Melissa Fernández-Pinto, Silvia García-Vicente, Alicia Garcia-Sanz, Arnau Mena-Molina, Olga Boix, Daniel Alcalá-López, Antonio Llombart-Cussac, Javier Cortés
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	BMC 2025-08-01
Serie:	Breast Cancer Research
Soggetti:	Ipatasertib PI3K/AKT Capecitabine Eribulin Gemcitabine plus carboplatin Non-taxane
Accesso online:	https://doi.org/10.1186/s13058-025-02089-4
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!